CXCR4

Assets acting on this target.

Class
CXCR4 antagonist (blocks CXCL12/SDF-1 binding)
Pathway
CXCR4/CXCL12 (SDF-1) axis blockade — mobilizes hematopoietic stem/progenitor cells from bone marrow niche into peripheral blood

CXCR4 is a G protein–coupled receptor expressed on hematopoietic stem and progenitor cells, certain immune cells, and many tumor cells. Its natural ligand, the chemokine CXCL12 (also called SDF-1), is produced by stromal cells within the bone marrow niche. Binding of CXCL12 to CXCR4 anchors stem cells in the marrow and helps recruit immune cells to sites of inflammation or malignancy. Small molecules and cyclic peptides that antagonize CXCR4 block this interaction, disrupting the retention signal and causing hematopoietic stem and progenitor cells to leave the marrow and enter the bloodstream, a process called mobilization. This is clinically useful when stem cells need to be collected from peripheral blood, such as for transplantation procedures. Beyond mobilization, the CXCR4/CXCL12 axis is implicated in cancer biology, where tumor cells exploit the same signaling to home to marrow niches, evade immune surveillance, or seed metastases, and in fibrotic and inflammatory diseases where aberrant chemokine signaling sustains cell recruitment. CXCR4 antagonism is therefore explored both as a supportive mobilization strategy and, more speculatively, as a way to interfere with tumor–stroma interactions or immune cell trafficking in solid tumors and hematologic malignancies.

By indication

CXCR4 drugs compared

4 drugs, stage by indication
4 drugs acting on CXCR4: developer, modality, furthest stage and stage in each indication. Furthest stage first.
DrugDeveloperModalityFurthest stageStage by indication
MotixafortideAyrmid Ltd., BioLineRx Ltd., Gloria BiosciencespeptideApprovedApproved in Multiple Myeloma; Phase 2 in Pancreatic Cancer
PlerixaforSanofismall moleculeApprovedApproved in Multiple Myeloma
Burixafor (TG-0054)Exicure, Inc., GPCR Therapeutics, Inc.small moleculePhase 2Phase 2 in Multiple Myeloma
AD-214AdAltabiologic (i-body)Phase 1Phase 1 in Chronic Kidney Disease

← all mechanisms